Agathos Biologics

Our mission as the good science company is to create biotechnology products and services within a strong ethical and moral framework that benefits everyone.

[Agathos Biologics @AgathosBio]

A welcome change in policy that will provide resources for ethical sources of cells and tissues for research and biomanufacturing.
https://t.co/9CpHJut9sR

#EthicalResearch #Biomanufacturing #GeneTherapy

[Agathos Biologics @AgathosBio]

Great news for patients with Wiskott-Aldrich syndrome!
https://t.co/TqGKBc0r9T

[Agathos Biologics @AgathosBio]

🦠Customized rAAV solutions for your unique research goals

Choose Agathos Biologics for personalized Adeno-associated virus solutions tailored to your research requirements. https://t.co/9p5bNEfuWN #genetherapy #aav #biotechnology

[Agathos Biologics @AgathosBio]

🔬 Join us at the 27th Annual Meeting of the American Society of Gene and Cell Therapy, where Agathos Biologics unveils groundbreaking data on our AE1-BHK cell line for viral vector production! #ASGCT #genetherapy
https://t.co/x7sk9Q4IPM

[Agathos Biologics @AgathosBio]

🌟 BREAKTHROUGH NEWS 🌟 The FDA has approved Lenmeldy, the first gene therapy for children with Metachromatic Leukodystrophy (MLD). This treatment offers hope to those affected by this rare genetic disease. #genetherapy https://t.co/E3pG6gWDWo

[Agathos Biologics @AgathosBio]

@TheScientistLLC recently published an article discussing AAV gene therapy and the future of tackling neurological disorders. https://t.co/wVrjdDrRfD

[Agathos Biologics @AgathosBio]

🔬 Breaking News: Agathos Biologics launches recombinant adeno-associated virus production (rAAV) service using novel AE1-BHK cell line https://t.co/HXtCFHOujS #genetherapy #viralvectors

[Agathos Biologics @AgathosBio]

🌍 Today, on Rare Disease Day, we stand with 300 million individuals worldwide facing the challenges of rare diseases. Since 2008, this global movement has united communities, advocating for equitable healthcare, timely diagnosis, and accessible treatments. #RareDiseaseDay2024

[Agathos Biologics @AgathosBio]

A recent study published in Cellular Reprogramming reveals promising results in extending lifespan and reversing age-related changes in mice using gene therapy-mediated partial reprogramming. https://t.co/nm60dKlwxS… #genetherapy #aav #biotech

[Agathos Biologics @AgathosBio]

🔬✨ Illuminate the intricacies of cellular biology with Agathos Biologics' advanced imaging techniques! Our high-throughput, multiparametric cell painting service enables you to delve deep into the inner workings of cells like never before. Contact us today! [email protected]

[Agathos Biologics @AgathosBio]

Gene Therapy Restores Hearing Loss in 11-Year-Old After Just One Month! 🌟 Akouos, a subsidiary of Eli Lilly, achieves groundbreaking success in the AK-OTOF-101 study. Witness the transformative power of gene therapy: https://t.co/QWa1k3NJRI #GeneTherapy

[Agathos Biologics @AgathosBio]

According to DelveInsight Business Research LLP, AAV gene therapy is poised for significant growth and continues to be a promising space for transformative advancements. #genetherapy https://t.co/eAA5fhx7GY

[Agathos Biologics @AgathosBio]

Gene therapy, led by adeno-associated viruses, holds promise for tackling hepatocellular carcinoma. Despite lacking specific trials, AAVs' safety and efficacy in diverse diseases hint at a revolutionary path in liver cancer treatment. #GeneTherapy
https://t.co/1gIFbkcRJd

[Agathos Biologics @AgathosBio]

@NeuExcell NXL-004, the world's first AAV gene therapy for malignant glioma, has been granted Orphan Drug Designation by the FDA. This innovative treatment brings hope for improved outcomes in the fight against this devastating condition. https://t.co/xHpKGiDxS6 #genetherapy

[Agathos Biologics @AgathosBio]

Researchers at Indiana University School of Medicine have discovered a game-changing liver pathway that may pave the way for change in immunomodulation strategies for gene therapy. https://t.co/BI6TdLZi6G #aav #GeneTherapy

[Agathos Biologics @AgathosBio]

AskBio to begin the first subjects in Phase I AAV gene therapy trial. The AB-1005 gene therapy is being analyzed for the treatment Parkinson’s disease. Looking forward to the outcomes and the positive impact on patients' lives! https://t.co/Jm5fl6EGtM #genetherapy

[Agathos Biologics @AgathosBio]

Elevate your AAV research to new heights with Agathos' Analytical Services! 🧬

Unlock the power of precise AAV titering through our cutting-edge dPCR technology, setting the gold standard for accuracy in quantification. https://t.co/WBdo7UCIAq #ViralVector #GeneTherapy

[Agathos Biologics @AgathosBio]

US Pharmacopeia has published <1040> Quality Considerations for Plasmid DNA as a Starting Material for Cell and Gene Therapies. Agathos CEO @JWBrownPhD participated in the Expert Panel that developed the draft. Please consider commenting!
https://t.co/yADH37S3MM

[Agathos Biologics @AgathosBio]

Concordia College receives a $2.5 million NSF grant for STEM scholarships. Agathos is proud to support the CLIMB program, which prepares students for impactful careers in the rapidly growing biotechnology sector. https://t.co/19poi6iiQ2 #Fargo #stem #northdakota #concordiacollege

[Agathos Biologics @AgathosBio]

Agathos Biologics' CEO, James Brown, presented at the Alliance for Regenerative Medicine's Meeting on the Mesa and highlighted Agathos' ongoing efforts in creating innovative cell lines to produce adeno-associated viruses. https://t.co/z0hp8SbyLC #meetingonthemesa #GeneTherapy